Adenylate cyclase is a membrane-bound enzyme that catalyses the conversion of ATP into cAMP upon activation of cell-surface G-protein-coupled receptors, such as β-adrenergic receptors, and initiates a cascade of phosphorylation reactions within the cell. Type 5 adenylate cyclase is a major isoform in the heart as well as in the striatum of the brain. Mice with a disrupted type 5 adenylate cyclase gene exhibited normal cardiac function under basal conditions, but a decreased response to isoprenaline stimulation. When mice were subjected to pressure overload stress with aortic banding, they developed cardiac hypertrophy, but with a significant reduction in the number of apoptotic cardiac myocytes as well as preserved cardiac function. When type 5 adenylate cyclase activity was inhibited pharmacologically, by the use of a novel P-site inhibitor with enhanced selectivity for this isoform, there were no changes in cardiac myocyte contractility, but the development of cardiac myocyte apoptosis induced by isoprenaline stimulation was effectively prevented. These results indicate that type 5 adenylate cyclase may serve as a better target of pharmacotherapy to prevent the development of cardiac myocyte apoptosis and thus failure in response to various cardiac stresses.
cascade, activating multiple proteins that regulate both the rate and force of cardiac contraction. Phosphorylation of the L-type calcium channel, for example, enhances calcium entry into cardiocytes, leading to increased contractility. Phosphorylation of phospholamban increases calcium uptake into the sarcoplasmic reticulum, thereby leading to a more rapid decrease in the cytosolic calcium concentration during diastole. Dissociation of the troponin-C-calcium complex is also enhanced when troponin-I is phosphorylated, which leads to an increased relaxation rate. These latter events underlie the lusiotropic effects of β-adrenergic stimulation. Thus a series of reactions occur within cardiocytes that are initiated by the production of cAMP by adenylate cyclase.
In the past decade, the cloning, structure and function of nine isoforms of mammalian adenylate cyclase have been reported [3] . On the basis of amino acid sequence, biochemical properties and tissue distribution, the nine isoforms can be subdivided into at least five subgroups. Type 1 and 8 adenylate cyclases form the neuronal group, which is mainly expressed in the brain. Type 2, 4 and 7 adenylate cyclases form the ubiquitous subgroup, which is expressed in multiple tissues. Type 3 adenylate cyclase is expressed in olfactory tissues as well as in atria and brown fat cells. Type 9 adenylate cyclase is widely expressed but shows different biochemical properties from those in the ubiquitous group. Type 5 and 6 adenylate cyclases are the major isoforms in the heart; type 5 adenylate cyclase is dominantly expressed in adult cardiac tissues and type 6 adenylate cyclase in fetal cardiac tissues [4] .
Role of type 5 adenylate cyclase in the heart
An interesting, as yet 'difficult to answer', question is why there are so many different isoforms of adenylate cyclase. The heart, for example, expresses at least seven isoforms of adenylate cyclase [5] . Because type 1 and 8 adenylate cyclase isoforms are neuron-specific, it means that the heart expresses all other isoforms. Out of these seven isoforms, type 5 adenylate cyclase is the major isoform expressed in adult cardiac tissues and is known to have high catalytic enzymatic activity and the property of G i -mediated inhibition [6] . An obvious question is then why this isoform is expressed dominantly in the heart.
We developed a mouse model with the disruption of this adenylate cyclase isoform (AC5KO). It was predictable that increases in cardiac function and heart rate in response to isoprenaline, a β-adrenergic receptor agonist, would be diminished in AC5KO mice. Since it was previously shown that the overexpression of type 5 adenylate cyclase in the heart enhanced cardiac function [7] , we had expected that baseline cardiac function and heart rate would be reduced in AC5KO mice. However, these changes were not observed. Despite the decrease in adenylate cyclase activity, basal cardiac function and heart rate were not decreased. Instead, baseline cardiac function tended to be elevated and heart rate was higher in AC5KO mice [5] .
Possible explanations include the diminished muscarinic receptor-or Ca 2+ -mediated inhibition of adenylate cyclase activity, because type 5 adenylate cyclase is known to be inhibited by G i and free Ca 2+ [8] . Indeed, muscarinic stimulation, which inhibits cardiac function and heart rate, was attenuated in AC5KO mice [5] . Atropine increased heart rate in the wild-type control, but not in AC5KO mice, indicating that the higher baseline heart rate was due to the loss of parasympathetic tone. Furthermore, arterial baroreflex slowing down of heart rate, which occurs through parasympathetic nerves, was also blunted in AC5KO mice. Thus type 5 adenylate cyclase may exert a major role in parasympathetic regulation of cardiac function as well as in sympathetic regulation. Furthermore, it is known that Ca 2+ influx through the L-type Ca 2+ channel is the primary pathway for initiation and maintenance and for the modulation of contractility by catecholamines. The increase in I Ca (Ca 2+ current) by the β-adrenergic agonist occurs via a cascade of events leading to protein kinase A-mediated phosphorylation of components associated with the Ca 2+ channel. In turn, cardiac adenylate cyclase is directly regulated negatively by low concentrations of Ca 2+ [8] . The lack of negative regulation of adenylate cyclase activity by Ca 2+ and G i may thus play a role in maintaining/elevating cardiac function in AC5KO mice.
Type 5 adenylate cyclase and cardiac stress
Determination of cardiac function in AC5KO mice demonstrated that this isoform may not play a major role in maintaining basal cardiac function. Then the next question is what is the role of this isoform under non-basal condition, e.g. under pathological conditions. Previous studies using transgenic models demonstrated that activation of the cAMP/protein kinase A pathway caused by the cardiac-specific overexpression of β-adrenergic receptors or G s α exacerbated heart failure [9, 10] , indicating that chronic stimulation of this pathway reduces cardiac function. In contrast, transgenic mice with cardiac-specific overexpression of type 6 adenylate cyclase did not develop cardiac dysfunction or myocardial fibrosis even in 19-month-old animals despite a clear increase in cardiac adenylate cyclase activity and cAMP levels [11] . Mice with type 8 adenylate cyclase overexpression also presented no signs of cardiomyopathy despite a clear increase in cardiac adenylate cyclase and protein kinase A activity [12] . Taken together, it appears that the role of adenylate cyclase in the development of heart failure differs from that of β-adrenergic receptors/G s α or among the isoforms of adenylate cyclase.
When AC5KO mice were subjected to pressure overload stress by thoracic aortic banding, cardiac function, left ventricular ejection fraction (as measured by echocardiography) and the left ventricular weight/body weight ratio were not different between the wild-type and AC5KO mice at baseline and 1 week after banding [13] . The left ventricular weight/body weight ratio was similar also at 3 weeks. However, cardiac function became significantly lower in the wild-type mice at 3 weeks with marked left ventricular dilatation. The number of apoptotic myocytes was similar at baseline but 2-fold greater at 1 week in the wild-type.
A potential mechanism for this favourable effect produced by disruption of type 5 adenylate cyclase included the upregulation of bcl-2 protein, an inhibitor of apoptosis; its expression was enhanced in AC5KO mice. It is well known that bcl-2 family proteins are post-transcriptionally regulated in an inhibitory manner, i.e. phosphorylation by protein kinase A and/or Akt, and thus regulation of stability of bcl-2 is achieved [14] . Accordingly, it is possible that the disruption of type 5 adenylate cyclase may lead to increased stability and thus expression of bcl-2. Nevertheless, limiting β-adrenergic signalling at the level of a specific adenylate cyclase isoform, i.e. the type 5 isoform, significantly prevented the development of cardiac dysfunction by decreasing the occurrence of cardiac myocyte apoptosis [13] .
Type 5 adenylate cyclase-targeted drug
If the disruption of type 5 adenylate cyclase is favourable, the future development of pharmacotherapy towards the activity of type 5 adenylate cyclase, not the entire β-adrenergic receptor signalling, may be useful [15] . Pharmacological inhibition of cAMP signalling, by the use of β-adrenergic receptor antagonists, has been widely utilized to reduce cardiac function in the treatment of high blood pressure for several decades. More recently, β-adrenergic receptor antagonists have been used in the treatment of heart failure, i.e. in hearts with deteriorated cardiac function. This paradoxical usage of β-adrenergic antagonists has been rationalized by the protection of the heart from excessive sympathetic stimulation and thus the prevention of cardiac myocyte from apoptosis [16] . However, major complications in introducing β-adrenergic antagonist therapy include the deterioration of cardiac function, especially in advanced heart failure, and deterioration of respiratory function due to its poor tissue selectivity because β-adrenergic receptors are expressed in lungs as well [17] . In this regard, adenylate cyclase, the target enzyme of β-adrenergic signalling, is made of multiple isoforms that have distinct tissue distributions. For example, type 5 adenylate cyclase is dominantly expressed in adult hearts, but not in lungs.
All adenylate cyclase isoforms share a common pharmacological property; the catalytic activity of each of them is inhibited by P-site inhibitors, i.e. adenosine analogues [18] , which inhibit adenylate cyclase through binding to the same site as the substrate ATP within the enzyme molecule [19] . Recently, a new series of P-site inhibitors with metal chelating property were developed [20] , in which the adenine ring and hydroxamic acid were joined to chelate the bivalent cation, Mg 2+ , which is essential to form the substrate complex of Mg-ATP for adenylate cyclase. It was then found that PMC-6 [1R,4R-3-(6-aminopurin-9-yl)-cyclopentanecarboxylic acid hydroxyamide] inhibited type 2 and 3 adenylate cyclases to a similar and modest degree, but very potently inhibited type 5 adenylate cyclase [21, 22] . The isoform selectivity of PMC-6 for type 5 adenylate cyclase appeared greater than that of NKY80, the most selective known inhibitor of type 5 adenylate cyclase so far [23] , but not membrane-permeable. Indeed, PMC-6 exhibited the lowest IC 50 value for type 5 adenylate cyclase, which was lower by 50-fold when compared with NKY80 or 3 -AMP. Thus PMC-6 is the most potent and selective inhibitor of type 5 adenylate cyclase among these compounds. A Lineweaver-Burk plot analysis demonstrated that the mode of inhibition by PMC-6 was not competitive with respect to ATP. PMC-6 did not interfere with the activity of protein kinase A, which also uses ATP as substrate [22] .
PMC-6 selectively and potently inhibited type 5 adenylate cyclase catalytic activity as well as cAMP accumulation in intact cardiac myocytes. It should be noted that the stimulation of β-adrenergic receptors with catecholamines enhances cardiac myocyte contractility through the production of cAMP and thus protein kinase A-mediated phosphorylation of phospholamban or the L-type calcium channel. However, the concentration of isoprenaline required for the maximal enhancement of cardiac contractility is much lower than that required for the maximal activation of cAMP production, suggesting that a large reserve capacity of producing cAMP by adenylate cyclase plays a role in regulating cardiac contractility [24] (Figure 1 ). Indeed, a low concentration of isoprenaline (10 nM) only marginally (∼10% of maximal) increases cAMP accumulation, while this isoprenaline concentration is enough to evoke myocyte contraction. PMC-6 did not inhibit the cAMP accumulation induced by a low (10 nM) concentration of isoprenaline, but readily inhibited that induced by a high (>100 nM) concentration of isoprenaline. In contrast, PMC-6 did not inhibit isoprenalineinduced myocyte contractility even at 10 µM. Thus PMC-6 does not inhibit the effect of β-adrenergic receptor stimulation when the stimulation is small. PMC-6 is effective only when strong stimulation is present. Strong stimulation may occur under pathological conditions with excessive sympathetic activity. Such a strong stimulation is known to induce cardiac myocyte apoptosis and not just regulate myocyte contractility in vitro [10] . When myocytes were incubated in the presence of low concentrations of isoprenaline (<10 nM), there was no difference in the number of apoptotic myocytes even after 24 h of incubation. The number of apoptotic cells increased slightly (100 nM) and markedly (1 mM) with increased isoprenaline concentrations. This marked increase in the number of apoptotic cells was successfully prevented by PMC-6 [22] .
Role of type 5 adenylate cyclase
The inhibition of cardiac adenylate cyclase activity by a type 5-selective inhibitor can prevent isoprenaline-induced cardiac myocyte apoptosis, suggesting that this isoform plays a specific role in inducing cardiac myocyte apoptosis. The disruption of this adenylate cyclase isoform did not reduce basal cardiac function, but reduced the cardiac myocyte apoptosis induced by excessive pressure overload stress as mentioned above [5, 13] . Thus this adenylate cyclase isoform may play a greater role when the heart is exposed to an excessive amount of stress, but not when under no or little stress. Myocyte apoptosis, induced by strong β-adrenergic receptor stimulation as demonstrated by numerous investigators [10, 25] , was attenuated by inhibiting type 5 adenylate cyclase with PCM-6. Thus this isoform does not contribute to producing cAMP in response to weak β-adrenergic receptor stimulation or under basal conditions, but may serve as a reserve to produce cAMP when strong β-adrenergic receptor stimulation is present (see Figure 1) .
In conclusion, each adenylate cyclase isoform may possess a distinct role in mediating β-adrenergic receptor signalling in the heart and this difference may be important in coordinating various effects of sympathetic stimulation to regulate cardiac function.
